Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies’s likelihood of approval (LoA) and phase transition for B-Cell Chronic Lymphocytic Leukemia took place on 29 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies overview

Gene therapy is under development for the treatment of B cell malignancies including relapsed or refractory B-cell chronic lymphocytic leukemia (CLL) and B-cell lymphomas including non-Hodgkin lymphoma (iNHL), diffuse large b-cell lymphoma, transformed B-cell lymphoma, or high grade B-cell lymphoma, relapsed and refractory acute lymphocytic leukemia (ALL), chronic myelocytic leukemia (CML) and Burkitt Lymphoma. It is administered through intravenous route. The therapy comprises of autologous T-lymphocytes genetically modified to express a chimeric antigen receptor (CAR) targeting the B-cell antigen CD19 and armored with 4-1BBL (CD137L) transduced with retroviral vector. The therapy is developed based on the CAR (chimeric antigen receptor) and TCR (T cell receptors) technology platforms.

Bristol-Myers Squibb overview

Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Quick View Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies LOA Data

Report Segments
  • Innovator
Drug Name
  • Gene Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.